Volitionrx Ltd - Understand $vnrx stock

$VNRX Market Cap: $52.63 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$1.286M

TTM

Gross Margin

Net Earnings

-$30.10M

TTM

Current Assets

$6.801M

Q3 2024

Current Liabilities

$30.28M

Q3 2024

Current Ratio

22.46%

Q3 2024

Total Assets

$12.68M

Q3 2024

Total Liabilities

$35.32M

Q3 2024

Book Value

-$22.64M

Q3 2024

Cash

$5.414M

Q3 2024

P/E

-1.749

Nov 29, 2024 EST

Free Cash Flow

-$9.120M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	$775.3K	$306.4K	$90.04K	$13.43K	$17.10K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$50.00K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	153.04%	240.3%	570.25%	-21.44%							-100.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	$775.3K	$306.4K	$90.04K	$13.43K	$17.10K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$50.00K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Selling, General & Admin	$16.92M	$17.51M	$12.88M	$6.727M	$5.485M	$6.954M	$6.656M	$4.525M	$3.904M	$1.908M	$1.720M	$1.360M	$1.090M	$10.00K	$10.00K	$20.00K	$20.00K	$20.00K	$30.00K	$10.00K
YoY Change	-3.39%	35.96%	91.47%	22.65%	-21.12%	4.47%	47.08%	15.91%	104.59%	10.94%	26.47%	24.77%	10800.0%	0.0%	-50.0%	0.0%	0.0%	-33.33%	200.0%
% of Gross Profit
Research & Development	$18.43M	$14.57M	$15.54M	$14.53M	$9.673M	$10.30M	$7.515M	$6.454M	$6.102M	$4.044M	$2.500M	$2.770M	$1.520M		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	26.48%	-6.24%	6.94%	50.26%	-6.13%	37.12%	16.43%	5.78%	50.88%	61.76%	-9.75%	82.24%
% of Gross Profit
Depreciation & Amortization	$1.153M	$865.3K	$204.0K	$627.6K	$676.8K	$636.4K	$528.2K	$309.4K	$236.3K	$142.1K	$150.0K	$140.0K	$120.0K
YoY Change	33.2%	324.05%	-67.49%	-7.28%	6.35%	20.49%	70.7%	30.92%	66.28%	-5.25%	7.14%	16.67%
% of Gross Profit
Operating Expenses	$36.76M	$32.09M	$28.42M	$21.26M	$16.06M	$17.90M	$14.70M	$11.29M	$10.01M	$5.952M	$4.230M	$4.140M	$2.610M	$10.00K	$10.00K	$20.00K	$20.00K	$30.00K	$40.00K	$10.00K
YoY Change	14.57%	12.89%	33.69%	32.39%	-10.27%	21.79%	30.14%	12.86%	68.1%	40.71%	2.17%	58.62%	26000.0%	0.0%	-50.0%	0.0%	-33.33%	-25.0%	300.0%
Operating Profit	-$35.99M	-$31.78M	-$28.33M	-$21.25M
YoY Change	13.24%	12.17%	33.35%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2010	2009	2008	2007	2006	2005	2004
Interest Expense	-$128.3K	-$47.82K	$155.8K	$129.8K	-$14.20K	-$110.9K	-$73.13K	-$20.38K	$339.7K	-$2.420M			$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	168.3%	-130.69%	20.03%	-1014.08%	-87.2%	51.68%	258.83%	-106.0%	-114.04%
% of Operating Profit
Other Income/Expense, Net	$454.8K	$1.229M	$1.343M	$848.5K	-$41.93K			$545.3K	$131.1K	$0.00	$870.0K	$0.00
YoY Change	-63.01%	-8.48%	58.31%	-2123.66%				315.85%		-100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Pretax Income	-$35.68M	-$30.60M	-$26.99M	-$20.40M	-$16.10M	-$18.01M	-$14.77M	-$11.91M	-$9.535M	-$8.214M	-$3.710M	-$4.080M	-$2.610M	-$10.00K	-$10.00K	-$20.00K	-$20.00K	-$30.00K	-$40.00K	-$10.00K
YoY Change	16.6%	13.37%	32.31%	26.71%	-10.6%	21.93%	24.06%	24.86%	16.09%	121.39%	-9.07%	56.32%	26000.0%	0.0%	-50.0%	0.0%	-33.33%	-25.0%	300.0%
Income Tax								$0.00	-$4.600K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$35.32M	-$30.60M	-$26.99M	-$20.40M	-$16.10M	-$18.01M	-$14.77M	-$11.91M	-$9.530M	-$8.214M	-$3.710M	-$4.080M	-$2.610M	-$10.00K	-$10.00K	-$20.00K	-$20.00K	-$30.00K	-$40.00K	-$10.00K
YoY Change	15.43%	13.37%	32.31%	26.71%	-10.6%	21.93%	24.06%	24.92%	16.03%	121.39%	-9.07%	56.32%	26000.0%	0.0%	-50.0%	0.0%	-33.33%	-25.0%	300.0%
Net Earnings / Revenue	-4555.54%	-9986.71%	-29976.99%	-151859.55%	-94146.55%							-8160.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.50	-$0.55	-$509.2K	-$449.5K	-$410.9K	-$573.7K	-$559.7K	-$516.5K	-$537.5K	-$611.3K	-$0.34	-$0.44	-$0.45	-$0.01	$0.00	-$0.01	-$0.01	-$0.01	-$0.02	-$0.01

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Cash & Short-Term Investments	$20.73M	$10.87M	$20.58M	$19.44M	$16.97M	$13.43M	$10.12M	$21.68M	$5.916M	$2.139M	$890.0K	$380.0K	$350.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	90.76%	-47.2%	5.85%	14.61%	26.36%	32.73%	-53.34%	266.44%	176.58%	140.33%	134.21%	8.57%
Cash & Equivalents	$20.73M	$10.87M	$20.58M	$19.44M	$16.97M	$13.43M	$10.12M	$21.68M	$5.916M	$2.139M	$890.0K	$380.0K	$350.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Short-Term Investments
Other Short-Term Assets	$881.5K	$1.232M	$1.385M	$879.8K	$590.1K	$475.2K	$451.0K	$332.8K	$306.7K	$196.8K	$110.0K	$320.0K	$350.0K
YoY Change	-28.48%	-11.01%	57.42%	49.1%	24.18%	5.38%	35.5%	8.53%	55.85%	78.87%	-65.63%	-8.57%
Inventory
Prepaid Expenses
Receivables	$242.6K	$72.61K	$12.51K	$7.120K
Other Receivables	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$21.85M	$12.17M	$21.98M	$20.33M	$17.56M	$13.90M	$10.57M	$22.01M	$6.223M	$2.336M	$1.010M	$700.0K	$700.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	79.54%	-44.62%	8.1%	15.81%	26.28%	31.56%	-51.99%	253.73%	166.41%	131.26%	44.29%	0.0%
Property, Plant & Equipment	$6.073M	$6.012M	$5.295M	$5.497M	$3.363M	$3.120M	$3.481M	$2.119M	$783.8K	$288.6K	$60.00K	$90.00K	$20.00K
YoY Change	1.0%	13.56%	-3.69%	63.48%	7.79%	-10.38%	64.26%	170.35%	171.6%	380.98%	-33.33%	350.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.096M	$6.123M	$5.512M	$5.819M	$3.735M	$3.587M	$4.057M	$2.721M	$1.489M	$1.097M	$1.060M	$1.520M	$1.550M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-0.43%	11.09%	-5.28%	55.79%	4.14%	-11.6%	49.09%	82.73%	35.71%	3.52%	-30.26%	-1.94%
Total Assets	$27.95M	$18.30M	$27.49M	$26.15M	$21.29M	$17.49M	$14.62M	$24.73M	$7.712M	$3.433M	$2.070M	$2.220M	$2.250M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Accounts Payable	$3.211M	$3.043M	$1.542M	$1.540M	$627.3K	$807.2K	$351.7K	$281.2K	$712.2K	$0.00	$520.0K	$690.0K	$280.0K	$110.0K	$110.0K	$100.0K	$80.00K	$60.00K	$70.00K	$70.00K
YoY Change	5.53%	97.28%	0.19%	145.44%	-22.29%	129.48%	25.09%	-60.52%		-100.0%	-24.64%	146.43%	154.55%	0.0%	10.0%	25.0%	33.33%	-14.29%	0.0%
Accrued Expenses	$4.128M	$3.117M	$4.012M	$3.671M	$2.426M	$923.0K	$1.278M	$1.439M		$0.00
YoY Change	32.42%	-22.3%	9.28%	51.34%	162.81%	-27.8%	-11.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$50.00K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change											-100.0%
Long-Term Debt Due	$1.311M	$1.155M	$889.9K	$970.5K	$784.8K	$601.8K	$624.9K	$186.5K	$116.2K	$0.00
YoY Change	13.59%	29.74%	-8.3%	23.66%	30.41%	-3.7%	235.11%	60.43%
Total Short-Term Liabilities	$31.84M	$17.39M	$6.516M	$6.237M	$3.860M	$2.333M	$2.290M	$2.034M	$1.120M	$2.713M	$960.0K	$750.0K	$530.0K	$110.0K	$110.0K	$100.0K	$80.00K	$60.00K	$70.00K	$70.00K
YoY Change	83.12%	166.83%	4.48%	61.57%	65.43%	1.86%	12.64%	81.62%	-58.73%	182.61%	28.0%	41.51%	381.82%	0.0%	10.0%	25.0%	33.33%	-14.29%	0.0%
Long-Term Debt	$4.448M	$3.636M	$3.035M	$3.468M	$3.101M	$3.015M	$2.376M	$1.524M	$547.9K	$351.8K	$430.0K	$640.0K	$620.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	22.33%	19.79%	-12.5%	11.85%	2.84%	26.9%	55.89%	178.2%	55.75%	-18.19%	-32.81%	3.23%
Other Long-Term Liabilities	$378.1K	$400.1K	$217.3K	$151.8K	$131.9K
YoY Change	-5.51%	84.11%	43.13%	15.13%
Total Long-Term Liabilities	$4.826M	$4.036M	$3.252M	$3.620M	$3.233M	$3.015M	$2.376M	$1.524M	$547.9K	$351.8K	$430.0K	$640.0K	$620.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	19.57%	24.09%	-10.16%	11.98%	7.21%	26.9%	55.89%	178.2%	55.75%	-18.19%	-32.81%	3.23%
Total Liabilities	$35.75M	$20.87M	$9.546M	$9.810M	$7.093M	$5.349M	$4.667M	$3.558M	$1.668M	$3.065M	$1.390M	$1.380M	$1.160M	$110.0K	$110.0K	$100.0K	$80.00K	$60.00K	$70.00K	$70.00K
YoY Change	71.31%	118.63%	-2.69%	38.31%	32.61%	14.61%	31.17%	113.35%	-45.59%	120.49%	0.72%	18.97%	954.55%	0.0%	10.0%	25.0%	33.33%	-14.29%	0.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $52.634 Million

About VOLITIONRX LTD

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 110 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Industry: In Vitro & In Vivo Diagnostic Substances Peers: Xtant Medical Holdings, Inc. RxSight, Inc. Sanara MedTech Inc. United Health Products, Inc. ORASURE TECHNOLOGIES INC RETRACTABLE TECHNOLOGIES INC PROJECT SAGE OLDCO, INC. TELA Bio, Inc. UTAH MEDICAL PRODUCTS INC